AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27273879
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition (TPN) - 30 kcal/kg/day, 0.16 gN/kg/day for 12 hours prior to operation
Trial: 27273879
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion for 12 hours prior to operation
Trial: 20703197
Drug: Paliperidone extended-release
RxNorm normalized name: Paliperidone Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paliperidone extended-release (ER) tablets, 3-15 mg/day (9 mg starting dose)
Trial: 20703197
Drug: Paliperidone extended-release
RxNorm normalized name: Paliperidone Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paliperidone extended-release (ER) tablets
Trial: 17113683
Drug: Tramadol/acetaminophen 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol/acetaminophen 75 mg/650 mg
Trial: 17113683
Drug: Hydrocodone/acetaminophen 7.5
RxNorm normalized name: hydrocodone/acetaminophen 7.5 mg-750 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone/acetaminophen 7.5 mg/650 mg
Trial: 16292444
Drug: Pro Root
RxNorm normalized name: Climara Pro
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pro Root MTA (Dentsply) with 2% methylene blue solution
Trial: 16292444
Drug: Zinc oxide-eugenol
RxNorm normalized name: Eugenol
DrugBank: Eugenol (DB09086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc oxide-eugenol cement (ZOE) with 2% methylene blue solution
Trial: 12111134
Drug: (131)I‐Lipiodol combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (131)I‐Lipiodol combined with low-dose cisplatin (30 mg/m2)
Trial: 12111134
Drug: (131)I‐Lipiodol therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (131)I‐Lipiodol therapy alone
Trial: 12111134
Drug: (131)I‐Lipiodol combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (131)I‐Lipiodol combined with low-dose cisplatin
Trial: 1977779
Drug: Not taking
RxNorm normalized name: Lamictal 25mg-100mg Tablet Starter Kit (For Patients Not Taking Enzyme-Inducing Drugs or Valproate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not taking beta-blocker
Trial: 20690865
Drug: Tibolone (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone (daily tablet for 6 months)
Trial: 20690865
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no hormone therapy)
Trial: 16420289
Drug: NG ‐monomethyl‐L‐arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NG ‐monomethyl‐L‐arginine (L‐NMMA)
Trial: 8280821
Drug: sucralfate gel
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sucralfate gel (Gastrogel)
Trial: 8280821
Drug: sucralfate suspension
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sucralfate suspension
Trial: 3449067
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of piretanide (6 mg)
Trial: 3449067
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of piretanide (6 mg)
Trial: 29635492
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic Acid (FA) supplementation (400 µg/d)
Trial: 27490103
Drug: Soy isoflavones
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavones (2 capsules of 20 mg per day) and placebo of vitamin D (P+S)
Trial: 25406653
Drug: Low-dose XJXGF
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose XJXGF (10% of the XJXGF formula)
Trial: 10232562
Drug: Epoprostenol (prostaglandin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoprostenol (prostaglandin I2), 500 microg intravenous bolus before cold perfusion
Trial: 8553333
Drug: Doxazosin, 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin, 4 mg daily
Trial: 1704153
Drug: Tetracycline 1
RxNorm normalized name: tetracycline 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline 1 g
Trial: 6405939
Drug: 5% acyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% acyclovir cream applied topically five times a day for five days
Trial: 24372302
Drug: Open-irrigated radiofrequency
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-irrigated radiofrequency catheter ablation (oiRFA) with saline volume administration
Trial: 24372302
Drug: Furosemide administration
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide administration during LA ablation
Trial: 18451770
Drug: Entrée with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entrée with reduced energy density (1.2 kcal/g)
Trial: 18451770
Drug: Entrée with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entrée with decreased portion size (300 g)
Trial: 18451770
Drug: Entrée with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entrée with standard energy density (1.6 kcal/g)
Trial: 31031186
Drug: 80 kV
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 kV tube voltage, 350 mgI/kg contrast dose, ASIR‐V from 40% to 100%
Trial: 31031186
Drug: 120 kV
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 120 kV tube voltage, 600 mgI/kg contrast dose, 40% ASIR
Trial: 27744624
Drug: SYM-1219 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYM-1219 (2 g secnidazole) with EE2 (0.035 mg) and NET (1 mg) tablets
Trial: 27744624
Drug: SYM-1219 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYM-1219 (2 g secnidazole) followed by EE2 (0.035 mg) and NET (1 mg) tablets 1 day later
Trial: 25395378
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg/day orally
Trial: 20346518
Drug: Escitalopram 10
RxNorm normalized name: escitalopram 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 10 mg daily for 12 weeks
Trial: 17566844
Drug: docetaxel 70
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel 70 mg/m(2) and carboplatin AUC 5
Trial: 17566844
Drug: paclitaxel 175
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: paclitaxel 175 mg/m(2) and carboplatin AUC 5
Trial: 18400730
Drug: Sunflower-oil capsules
RxNorm normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunflower-oil capsules (3 g/d; control)
Trial: 18400730
Drug: Cod (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cod (3 x 150 g/wk)
Trial: 18400730
Drug: Salmon (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmon (3 x 150 g/wk)
Trial: 18400730
Drug: Fish-oil capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish-oil capsules (3 g/d)
Trial: 17038942
Drug: Recombinant activated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant activated factor VII (rFVIIa) at doses of 40, 80, or 160 mug/kg
Trial: 12655421
Drug: Daily inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily inhalation plus daily hydrotherapy
Trial: 12655421
Drug: Daily inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily inhalation of normal saline (control)
Trial: 11250737
Drug: Mathematical models
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mathematical models for evaluating operative therapy
Trial: 11250737
Drug: Mathematical models
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mathematical models for chemotherapy administration
Trial: 1439943
Drug: 2% clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% clindamycin vaginal cream (5 g applied intravaginally at bedtime for 7 days) with placebo oral tablets twice daily for 7 days
Trial: 1439943
Drug: Oral metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral metronidazole tablets (500 mg twice a day for 7 days) with placebo vaginal cream (5 g intravaginally for 7 days)
Trial: 16005362
Drug: Goshajinkigan (GJG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goshajinkigan (GJG) 7.5 g/day for 1 month
Trial: 16005362
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no GJG treatment)
Trial: 9358963
Drug: nisoldipine CC
RxNorm normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nisoldipine CC
Trial: 9358963
Drug: combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination therapy (nisoldipine CC and lisinopril)
Trial: 1389940
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg zidovudine after a 25 g protein meal
Trial: 1389940
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg zidovudine in a fasting state
Trial: 3930309
Drug: Deteclo (tetracycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deteclo (tetracycline hydrochloride, chlortetracycline hydrochloride, and demeclocycline hydrochloride 300 mg)
Trial: 27348923
Drug: Conical stone
RxNorm normalized name: ditch stonecroft extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conical stone needle on foot combined with bian anvil at Yintang (CV 29), applied at Yongquan (KI 1), Taichong (LR 3), and Gongsun (SP 4) for 2 weeks, once a day with 2 days rest between treatments.
Trial: 27348923
Drug: Common acupuncture
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common acupuncture at Sanyinjiao (SP 6), Shenmen (HT 7), and Sishencong (EX-HN 1) for 2 weeks, once a day with 2 days rest between treatments.
Trial: 27348923
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups were followed up after treatment.
Trial: 24682079
Drug: Ultrasound-guided bilateral
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided bilateral thoracic paravertebral block with 0.25% ropivacaine 0.5 mL/kg and 1:200,000 epinephrine
Trial: 24682079
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (intravenous PCA)
Trial: 23006443
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (Bisocard® 10 mg)
Trial: 23006443
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (Concor 10®)
Trial: 17629805
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level laser therapy (LLLT) with dosage 1.5 J/per point, applied once a day for 10 days.
Trial: 17629805
Drug: Placebo laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo laser therapy (control group).
Trial: 9432092
Drug: Maximal graded
RxNorm normalized name: Spirulina maxima preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximal graded treadmill test (VO2max = 30.3 +/- 5.7 mL x min‐1 x kg‐1)
Trial: 3103412
Drug: Intermittent transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent transdermal nitroglycerin (16 hours/day)
Trial: 3103412
Drug: Continuous transdermal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous transdermal nitroglycerin (24 hours/day)
Trial: 3103412
Drug: Control value
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control value (before treatment)
Trial: 25867538
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (5 mg dose intravenously)
Trial: 12815913
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens (CEE), 0.625 mg/d, and medroxyprogesterone acetate (MPA), 5 mg/d
Trial: 12815913
Drug: Tibolone, 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone, 2.5 mg/d
Trial: 8774205
Drug: Oral estradiol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol, 2 mg/d for the first 6 months
Trial: 1465288
Drug: Dexamethasone (DXM)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DXM) with metoclopramide (MCP) 1.5 mg/kg (group B)
Trial: 1465288
Drug: Dexamethasone (DXM)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DXM) with metoclopramide (MCP) 2 mg/kg (group D)
Trial: 1465288
Drug: Metoclopramide (MCP)
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoclopramide (MCP) 1.5 mg/kg (group A)
Trial: 1465288
Drug: Metoclopramide (MCP)
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoclopramide (MCP) 2 mg/kg (group C)
Trial: 25748642
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of brinzolamide 1% and timolol 0.5% (FCBT)
Trial: 25022107
Drug: Acupoint injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint injection combined with plum-blossom needle
Trial: 25022107
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication (control group)
Trial: 15936419
Drug: Three rounds
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three rounds of oral visual inspection by trained health workers at 3-year intervals (intervention group)
Trial: 12183788
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg depot dexamethasone combined with 60 mg lidocaine
Trial: 8758853
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 'Nao An' capsules
Trial: 6357037
Drug: Avoiding antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avoiding antibiotic prophylaxis
Trial: 29543123
Drug: Self‐administered Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self‐administered Foam Rolling (SAFR)
Trial: 28089316
Drug: Beta-blockers (time-dependent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers (time-dependent variable)
Trial: 26102300
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of HPMC and povidone
Trial: 24408214
Drug: High-dose (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose (35 mg) nicotine patch
Trial: 19200452
Drug: Single high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single high-dose regimen (1 x 12 microg)
Trial: 19200452
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen (2 doses of 6 microg with a 28-day interval)
Trial: 17971615
Drug: Computerized Dynamic
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized Dynamic Posturography (CDP) therapy
Trial: 17971615
Drug: Standard Physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Physical Therapy (PT)
Trial: 11209831
Drug: Measured total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measured total daily exposure time
Trial: 9743393
Drug: Epidural morphine-bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine-bupivacaine (0.05 mg/kg epidural morphine and 5 ml 0.25% bupivacaine followed by an infusion of 0.125% bupivacaine with 0.1% morphine)
Trial: 9743393
Drug: Intravenous PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous PCA morphine sulfate (0.1 mg/kg)
Trial: 9743393
Drug: Epidural morphine-bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine-bupivacaine
Trial: 9743393
Drug: Intravenous PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous PCA morphine sulfate
Trial: 28578639
Drug: ADT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADT plus abiraterone acetate (1000 mg daily) and prednisolone (5 mg daily)
Trial: 17201848
Drug: High BNP
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High BNP concentration (>18.4 pg/mL)
Trial: 8759075
Drug: Diltiazem (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (60 to 90 mg TID)
Trial: 6750282
Drug: Tolmetin (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolmetin (1,200 mg/day)
Trial: 6750282
Drug: Paracetamol (2,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (2,000 mg/day)
Trial: 24114668
Drug: Continuous erlotinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous erlotinib (100 mg daily)
Trial: 24114668
Drug: Intermittent erlotinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent erlotinib (150 mg on alternate days from day 2 to 14, then 150 mg daily on days 15 to 21)
Trial: 22120894
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg ginkgo extract tablets, three times daily for 30 days
Trial: 18369175
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and clopidogrel combined
Trial: 9167505
Drug: Sertindole 12
RxNorm normalized name: sertindole 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertindole 12 mg/day
Trial: 9167505
Drug: Haloperidol 4
RxNorm normalized name: haloperidol 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 4 mg/day
Trial: 9167505
Drug: Haloperidol 8
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol 8 mg/day
Trial: 7681897
Drug: Prazosin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (6 mg/day)
Trial: 23807186
Drug: Cataract surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cataract surgery plus intraoperative ranibizumab injection
Trial: 17081355
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride concluding heparin (control)
Trial: 14692654
Drug: TOR200 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOR200 (200 mg daily)
Trial: 14692654
Drug: TAM20 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAM20 (20 mg daily)
Trial: 11013867
Drug: Smoking group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking group (mean cotinine concentration 1039 +/- 560 mg/L in serum)
Trial: 4028282
Drug: Tinidazole 2
RxNorm normalized name: tinidazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole 2 g daily taken orally in two separate doses for two consecutive days
Trial: 15954914
Drug: EPO administration
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EPO administration (50 units per kg once per week) in group II
Trial: 15954914
Drug: No EPO
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No EPO treatment in group III
Trial: 8046602
Drug: Regular release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular release formulation of tiaprofenic acid (300 mg)
Trial: 8046602
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release (SR) formulation of tiaprofenic acid (300 mg)
Trial: 15114082
Drug: Celsior solution
RxNorm normalized name: Fraxinus excelsior leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celsior solution
Trial: 11602855
Drug: University of
RxNorm normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [University of Michigan]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: University of Wisconsin (U.W.) solution
Trial: 24394747
Drug: Buprenorphine Transdermal
RxNorm normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine Transdermal Delivery System (BTDS)
Trial: 16325366
Drug: Dexrazoxane supplementation
RxNorm normalized name: Dexrazoxane
DrugBank: Dexrazoxane (DB00380)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexrazoxane supplementation (400 mg/m²) after epirubicin infusion
Trial: 16325366
Drug: Epirubicin-based chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin-based chemotherapy without dexrazoxane